2018
Chapter 13 Interstitial Lung Disease in the Connective Tissue Diseases
Antin-Ozerkis D, Rubinowitz A, Evans J, Homer R, Matthay R. Chapter 13 Interstitial Lung Disease in the Connective Tissue Diseases. 2018, 157-185. DOI: 10.1016/b978-0-323-48024-6.00013-6.Peer-Reviewed Original ResearchConnective tissue diseaseInterstitial lung diseaseCTD-ILDTissue diseaseLung diseaseIdiopathic interstitial lung diseaseFulminant respiratory failureRespiratory failureImmunosuppressive agentsHealthy patientsDrug reactionsFirst manifestationGradual onsetDiagnostic approachDiseaseCareful searchCommon formSubtle evidenceTreatmentDyspneaCorticosteroidsCoughPatientsInfectionDiagnosis
2012
Interstitial Lung Disease in the Connective Tissue Diseases
Antin-Ozerkis D, Rubinowitz A, Evans J, Homer RJ, Matthay RA. Interstitial Lung Disease in the Connective Tissue Diseases. Clinics In Chest Medicine 2012, 33: 123-149. PMID: 22365251, DOI: 10.1016/j.ccm.2012.01.004.Peer-Reviewed Original ResearchConceptsConnective tissue diseaseInterstitial lung diseaseLung diseaseTissue diseaseIdiopathic interstitial lung diseaseFulminant respiratory failureCTD-ILDRespiratory failureImmunosuppressive agentsHealthy patientsDrug reactionsFirst manifestationGradual onsetDiseaseCareful searchSubtle evidenceDyspneaCorticosteroidsCoughPatientsInfectionDiagnosis
2010
Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical Development
Nassar A. Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical Development. 2010, 1-24. DOI: 10.1002/9780470571224.pse111.Peer-Reviewed Original ResearchDrug candidatesIdiosyncratic drug reactionsNew drug candidatesReactive metabolitesDrug discoveryDrug bioactivationDrug-metabolizing enzymesHuman drug-metabolizing enzymesPotential toxicitySafety profileDrug reactionsClinical developmentPreclinical phaseSubtle evidenceReactionRecent effortsToxicityMetabolitesCandidates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply